Lanean...
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Immunotherapy has recently emerged as a novel strategy for treating different types of solid tumors, with promising results. However, still a large fraction of patients do not primarily respond to such approaches, and even responders sooner or later develop resistance. Moreover, immunotherapy is a p...
Gorde:
| Argitaratua izan da: | J Clin Med |
|---|---|
| Egile Nagusiak: | , , , , |
| Formatua: | Artigo |
| Hizkuntza: | Inglês |
| Argitaratua: |
MDPI
2020
|
| Gaiak: | |
| Sarrera elektronikoa: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7141336/ https://ncbi.nlm.nih.gov/pubmed/32138216 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/jcm9030675 |
| Etiketak: |
Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!
|